Navigation Links
Resolve Initiates Phase 2 Clinical Study in SLE
Date:7/16/2014

SEATTLE, July 16, 2014 /PRNewswire/ -- Resolve Therapeutics, LLC announced today the initiation of a multi-dose, one month phase 2 clinical study with its lead compound RSLV-132 in systemic lupus erythematosus (SLE).

Following the successful completion of it phase 1 single dose safety study with RSLV-132, Resolve recently initiated a phase 2 study in lupus patients.  The study will be conducted at multiple sites in the U.S., and will investigate four dose levels, with multiple doses being administered over one month.  The study is designed to establish biological proof-of-concept for RSLV-132.

RSLV-132 is a novel Fc fusion protein consisting of human RNase attached to the Fc portion of human IgG.  The goal of the therapy is to reduce the burden of circulating RNA-containing immune complexes which are thought to be the most proximal trigger of the systemic inflammation characteristic of SLE.  By eliminating the RNA cargo contained in circulating immune complexes the therapy is designed to prevent chronic activation of nucleic acid sensing toll like receptors (e.g. TLR7 and TLR8) and subsequent activation of the interferon inflammatory cascade.  Additional therapeutic benefit is thought to result from dampening B-cell activation, as well as mitigation of the direct tissue damage caused by immune complex deposition in key organs, such as the kidney and brain.

"We are thrilled to move RSLV-132 one step closer to the large number of SLE patients that are not well controlled with current therapy" commented James Posada, chief executive officer of Resolve Therapeutics.

About Resolve Therapeutics
Resolve Therapeutics is a privately held biotechnology company based in Seattle that is dedicated to helping patients with lupus through the development of its platform of targeted nuclease therapeutics.  In addition to the lead mole
'/>"/>

SOURCE Resolve Therapeutics, LLC
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. RSC New England Clinicians to Present at RESOLVE New England’s 20th Annual Conference on November 2nd, 2013
2. New nanomedicine resolves inflammation, promotes tissue healing
3. WMIS Supports Experts, Commits to Resolve Beta Amyloid Issues with CMS
4. BioFit Helps Lab Specifiers Resolve to Improve Worker Safety and Productivity in 2013 through Ergonomic Seating Use
5. Cellectricon Launches Dynaflow® Resolve System Enabling Novel Ion Channel Assays
6. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
7. inVentiv Health Initiates Refinancing Transactions To Fund Continued Growth
8. EquitiesIQ Initiates Coverage of Alliqua, Inc.
9. OxThera Initiates Clinical Trial in Primary Hyperoxaluria
10. Empire Asset Management Company initiates coverage on INSPIRE MD with a Buy rating
11. Acacia Pharma Initiates Pivotal Phase 3 Studies with APD421 in Post-Operative Nausea & Vomiting (PONV)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Mass. Using a bio-mimicking analog of one ... grass, an international research team led by Alejandro ... taken a major step in developing long-sought polymer ... electricity for use in electronic devices. , ... Amherst and others at Stanford University and Dresden ...
(Date:9/30/2014)... , Sept. 30, 2014 Nematicide is ... nematodes. Nematodes are microscopic parasitic roundworms, found in ... inside other plants and animals. Nematicides have tended ... other properties promoting migration through the soil. A ... 1,000 plant-parasitic nematodes. With more than 10,000 species ...
(Date:9/30/2014)... Md. , Sept. 30, 2014  RegeneRx ... today announced that it has received a Canadian ... by Actin-Sequestering Peptides.  This patent includes claims using ... numerous other actin-sequestering peptides for these purposes.  The ... About RegeneRx Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
(Date:9/30/2014)... Los Angeles, CA (PRWEB) September 30, 2014 ... Separation (EWS), the high-speed, chemical-free process to clean up ... letter to shareholders, CEO Riggs Eckelberry reported on the ... West Texas, at a site provided by partner ... ramped up to 1000 barrels per day (bpd) and ...
Breaking Biology Technology:Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2
... from McGill,s Physics Department and Mike Lilly from Sandia ... electronic circuits. It is formed by two wires separated ... This discovery, published in the journal Nature Nanotechnology ... and power of the ever smaller integrated circuits of ...
... LONDON, December 7, 2011 Silence Therapeutics plc ... ( RNAi ) therapeutics company, announces a positive outcome from the ... (EPO) over opposition to Silence,s granted European Patent EP 1 536 ... The granted patent refers to the gene target PKN3, protein ...
... 2011  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) ... , 2.875% Convertible Senior Notes due February 15, 2015 ... $1,000 principal amount or approximately $6.44 per share, effective December ... May 1, 2015 (May 2015 Notes) is 135.9849 shares of ...
Cached Biology Technology:Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office 2Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office 3Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office 4PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes 2
(Date:9/30/2014)... think of nature as something that we enjoy when we ... Or do we think of ourselves as a part of ... what about a house? , The answers to these ... our actions, our speech and in cultural artifacts. , A ... Washington, the American Indian Center of Chicago and the Menominee ...
(Date:9/30/2014)... LA JOLLAJoseph Ecker, a Salk professor and Howard ... staff scientist, have been named recipients in the ... of Health (NIH) through the BRAIN (Brain Research ... in neuroscience. The grant, announced September 30, provides ... Salk scientists over three years. , The BRAIN ...
(Date:9/30/2014)... is available in German . ... the most expensive foods in the world. Because they grow ... But the distinctive smell of truffles is not only of ... under the direction of the Goethe University Frankfurt have discovered ... soil bacteria which are trapped inside truffle fruiting bodies. , ...
Breaking Biology News(10 mins):The cultural side of science communication 2Salk scientists receive $3 million for BRAIN Initiative grant 2On the trail of the truffle flavor 2
... A new discovery in stem cell research may mean big ... Ph.D., and a research team at the University of Kentucky ... journal. , The researchers genetically mapped a stem cell ... effort, carried the investigation all the way through to the ...
... at the University of Missouri-Columbia, recently found fossil evidence ... present-day Peru that showed people were eating domesticated chili ... chili peppers one of the oldest domesticated food sources ... the Feb. 15 edition of the journal Science. , ...
... When man made his way out of Africa some ... not alone: He was accompanied by the bacterium Helicobacter ... man and the bacterium spread throughout the entire world. ... of scientists led by Mark Achtman from the Max ...
Cached Biology News:Researchers first to map gene that regulates adult stem cell growth 2Researchers find 6,000-year-old fossil evidence 2Out of Africa -- Bacteria, as well 2
... a derivative of the pAcHLT-A Vector (Cat. No. ... (BFP), followed by a 6xHis tag and a ... BFP-6xHis fusion proteins when cloned into one of ... Sac I, Not I, Pst I, Kpn I, ...
Mouse monoclonal antibody to PDK2 - pyruvate dehydrogenase kinase, isoenzyme 2...
... pLivSelect is a direct antibiotic-based selection ... solely on colony survival, eliminating the need ... inexpensive process provides close to 100% accuracy ... ideal platform for robot colony picking. This ...
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
Biology Products: